Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 2
1968 2
1969 3
1970 2
1971 1
1977 1
1978 2
1979 4
1980 2
1981 1
1982 3
1983 2
1988 1
1989 1
1990 4
1991 4
1992 4
1993 3
1994 3
1995 5
1996 4
1997 20
1998 16
1999 21
2000 25
2001 16
2002 8
2003 13
2004 12
2005 17
2006 25
2007 12
2008 13
2009 19
2010 30
2011 33
2012 28
2013 28
2014 36
2015 32
2016 32
2017 30
2018 32
2019 37
2020 34
2021 33
2022 19
2023 25
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

622 results

Results by year

Filters applied: . Clear all
Page 1
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Hayden FG, et al. Among authors: shishido t. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. N Engl J Med. 2018. PMID: 30184455 Free article. Clinical Trial.
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Ison MG, et al. Among authors: shishido t. Lancet Infect Dis. 2020 Oct;20(10):1204-1214. doi: 10.1016/S1473-3099(20)30004-9. Epub 2020 Jun 8. Lancet Infect Dis. 2020. PMID: 32526195 Clinical Trial.
Antifungal compounds from cyanobacteria.
Shishido TK, Humisto A, Jokela J, Liu L, Wahlsten M, Tamrakar A, Fewer DP, Permi P, Andreote AP, Fiore MF, Sivonen K. Shishido TK, et al. Mar Drugs. 2015 Apr 13;13(4):2124-40. doi: 10.3390/md13042124. Mar Drugs. 2015. PMID: 25871291 Free PMC article.
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Sasaki M, Tabata K, Kishimoto M, Itakura Y, Kobayashi H, Ariizumi T, Uemura K, Toba S, Kusakabe S, Maruyama Y, Iida S, Nakajima N, Suzuki T, Yoshida S, Nobori H, Sanaki T, Kato T, Shishido T, Hall WW, Orba Y, Sato A, Sawa H. Sasaki M, et al. Among authors: shishido t. Sci Transl Med. 2023 Jan 18;15(679):eabq4064. doi: 10.1126/scitranslmed.abq4064. Epub 2023 Jan 18. Sci Transl Med. 2023. PMID: 36327352 Free PMC article.
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T, Nobori H, Fukao K, Baba K, Matsumoto K, Yoshida S, Tanaka Y, Watari R, Oka R, Kasai Y, Inoue K, Kawashima S, Shimba A, Hayasaki-Kajiwara Y, Tanimura M, Zhang Q, Tachibana Y, Kato T, Shishido T. Kuroda T, et al. Among authors: shishido t. J Antimicrob Chemother. 2023 Apr 3;78(4):946-952. doi: 10.1093/jac/dkad027. J Antimicrob Chemother. 2023. PMID: 36760083 Free PMC article.
Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H, Fukao K, Kuroda T, Anan N, Tashima R, Nakashima M, Noda S, Tajiri M, Torii M, Toba S, Uemura K, Sanaki T, Shishido T, Tachibana Y, Kato T. Nobori H, et al. Among authors: shishido t. J Antimicrob Chemother. 2022 Oct 28;77(11):2984-2991. doi: 10.1093/jac/dkac257. J Antimicrob Chemother. 2022. PMID: 35914182 Free PMC article.
622 results